SOMATOSTATIN ANALOGS THERAPY OF NEUROENDOCRINE TUMOURS
I. Puliafito, E. Leotta, G. Blanco, C. Colarossi, C. Caltavuturo, G. Primavera, M. P. Vitale, C. Puglisi, D. Giuffrida
Vol.4 (2019), issue 2, pag. 4 - 11
| Received | 30/09/2019 |
| Accepted | 07/10/2019 |
| Published | 10/10/2019 |
| Review by | Single-blind |
ABSTRACT
BACKGROUND: Gold standard therapy in patients a ected by well-dif- ferentiated (WD) neuroendocrine tumors (NET) is based on somatosta- tin analogs (SSAs) as Lanreotide (LAN); Lanreotide is conventionally administrated at a dose of 120 mg every weeks (1q28). Potential advers reactions are related to anti-secretive e ects of activation of somatostatin’s receptor.
AIM: e purpose of this study was to evaluate the administration of high doses of Lanreotide 120 mg every three weeks (1q21) in patients with WD NET advanced in progression a er rst line therapies in six elderly patients.
RESULTS: Evaluated patients included 5 females and 1 male (mean age was 79,5 yeas, median age 80 years, range 74-84 yo). ree patients had NETs G2, other three patients NETs G1. All patients showed radiologic progression disease documented during therapy with standard dose of SSAs. One patient had radiological partial response a er treatment with LAN autogel, four patients had stable disease and one patient progression of neuroendocrine neoplasm. No serious adverse events have been recor- ded during this study.
CONCLUSION: Interval reduction of SSAs can be considered for elderly patients with advanced NET G1-G2 a er progression with standard the- rapy as our results has demonstrated during this experience.